CytoCore Inc. (OTCBB:CYOE), the developer of cost-effective, highly
accurate screening systems for early detection of gynecological cancers
and sexually transmitted diseases, today announced that it has received
the report of the Interim Analysis that was performed on the data from
its clinical trial on Adequacy, Efficacy and Safety between the SoftPAP®
Collector Compared to Standard Spatula/CytoBrush Technique
(NCT00474968). The Interim Analysis included data from approximately 300
patients of the 650 patient trial. Based on the data reviewed in the
Interim Analysis, statistically significant differences between the SoftPAP®
Collector and the Standard Spatula/CytoBrush Technique are noted in the
report. CytoCore considers the trends shown in this report to be
promising.
At current enrollment rates this trial is expected to close in May of
2008 with the final results being available in July 2008.
CytoCore develops cost-effective, highly accurate screening systems for
early detection of gynecological cancers and sexually transmitted
diseases. Designed for easy deployment at a laboratory or at the
point-of-care, the CytoCore suite of sample collection technologies
assists in the detection of cervical, endometrial, and other cancers, as
well as the human Papilloma virus. The CytoCore Solutions™
System is being developed to provide medical practitioners with highly
accurate, low-cost, cervical and uterine cancer screening systems that
can be seamlessly integrated into existing medical models. More
information is available at: www.CytoCoreInc.com.
Certain statements in this release are forward-looking. These statements
are based on CytoCore's current expectations and involve many risks and
uncertainties, such as the company's inability to obtain sufficient
financing, the possibility that clinical trials will not substantiate
CytoCore's expectations with respect to the CytoCore Solutions™
System, and other factors set forth in reports and documents filed by
CytoCore with the Securities and Exchange Commission. Actual results may
differ materially from CytoCore's current expectation depending upon a
number of factors affecting the Company's business. These factors
include, among others, risks and uncertainties detailed in the Company's
periodic public filings with the Securities and Exchange Commission,
including but not limited to the Company's Annual Report on Form 10-K
for the year ended December 31, 2006. Except as expressly required by
law, CytoCore undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
CytoCore, Inc. Robert McCullough, Jr., 312-222-9550 or EVC
Group Douglas Sherk/Matthew Selinger, 415-896-6820 mselinger@evcgroup.com
